
Robert Adelman
QuietNamed in filings at Venbio Global Strategic
- Board seats filed
- 5

Named in filings at Venbio Global Strategic
all filings on record
last 24 months
from a verified or cited source
| TP Therapeutics | Biotech & pharma | October 2018 | SR One, Vivo Capital |
| Apellis Pharmaceuticals | Biotech & pharma | December 2015 | Sofinnova Venture Partners |
| PRECISION BIOSCIENCES | Biotech & pharma | April 2015 | None on file |
| Metacrine | Biotech & pharma | January 2015 | ARCH Venture Partners, Polaris Partners |
| Solstice Biologics | Biotech & pharma | September 2014 | Cure Ventures |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The category is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Categories of companies where filings name Robert Adelman on the board, based on 5 filed seats with a verified or cited source.